Azaftig stimulates in vitro lipolysis by rodent and human adipocytes.
Azaftig is an urinary proteoglycan present in some cancer and AIDS patients experiencing weight loss. Administration of azaftig to mice results in weight loss that is associated with loss of fat depot. So far, very little is known about the mechanism underlying loss of fat depot in mice or weight loss in patients excreting azaftig. Augmentation of lipolysis may be one mechanism that can cause reduction of fat depot. Therefore, the present study was designed to examine the effect of azaftig on lipolysis by adipocytes derived from obese rats and humans. Results show a dose-dependent potentiation of lipolysis by azaftig in both rat and human adipocytes.
Figueroa
Julio E
JE
Department of Medicine (Sections of Infectious Disease, Cardiology and Endocrinology), and Stanley S. Scott Cancer Center, Box T4M5, LSU Health Sciences Center, 1542 Tulane Ave, New Orleans, LA 70112, USA.
Vijayagopal
Parakat
P
Prasad
Chandan
C
D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008066:Lipolysis / Q000187:drug effects; D009765:Obesity / Q000378:metabolism* / Q000652:urine; D011509:Proteoglycans / Q000494:pharmacology*; D051381:Rats; D011924:Rats, Zucker
D011509:Proteoglycans; C118838:azaftig